Most Read Articles
29 Nov 2017
Rapid onset opioids may allow for more effective treatment of breakthrough cancer pain as their pharmacokinetic profile closely mimics the pain’s time course
Christina Lau, 22 Oct 2015
A 21-gene expression assay can identify patients with early-stage breast cancer who can skip adjuvant chemotherapy without facing an increased risk of recurrence at 5 years.
Cathy Chow, PhD, 27 Aug 2015

HER2-positive breast cancer tends to be more aggressive, has worse patient prognosis, and responds less to treatment. A two-pronged approach to block the HER pathway via pertuzumab (Perjeta®, Roche), a first-in-class HER dimerization inhibitor, in combination with trastuzumab and chemotherapy, may offer more treatment options for HER2-positive metastatic breast cancer patients as well as those with early breast cancer. 

Saras Ramiya, 25 Oct 2017
The first patient-reported outcomes study on durvalumab treatment after chemoradiation in locally advanced non-small cell lung cancer (NSCLC) shows patients’ quality of life is similar to that of the patients who received placebo.

Patients with genital warts at high risk of cancer

25 Aug 2017
Teen girls, due to insecurity, are turning to labiaplasty to measure up to physical perfection.

Patients with genital warts have higher risk of cancers related to human papillomavirus (HPV) infection, particularly anogenital malignancies, a new study has shown.

During the study period, 21,763 patients (59.67 percent female) developed genital warts, with the incidence being highest in the 20 to 29 age group. During follow-up, 1,002 (4.60 percent) cancer cases were recorded with a mean time to cancer diagnosis of 4.17±3.06 years.

Of the 1,002 cancer patients, 69.96 percent (n=701) were female while 30.04 percent (n=301) were male (standardized incidence ratio [SIR] compared to general population, 1.95; 95 percent CI, 1.83 to 2.07).

Excess risk was marginally higher in males (SIR, 1.87; 1.66 to 2.08) than in females (SIR, 1.80; 1.66 to 1.93) because of anogenital cancers in the anus and penis (SIR, 5.87; 2.04 to 9.71) and HPV-related cancers (SIR, 13.57; 3.52 to 23.62). Females had higher risk of anogenital cancers in the cervix in situ (SIR, 3.34; 2.20 to 4.48).

The risk of smoking-related malignancies, such as cancers of the pharynx, oesophagus, larynx, liver and pancreas, among others, were markedly higher in males (SIR, 1.83; 1.47 to 2.19) and females (SIR, 1.88; 1.40 to 2.36) compared to the general population.

Specifically, risk of lung cancer in males (SIR, 2.0; 1.4 to 2.8) and kidney cancer in females (SIR, .41; 1.19 to 3.63) were higher than in the general population.

Data used in the study were retrieved from the National Health Insurance Research Database of Taiwan. Only those diagnosed with genital warts were included. Patients who had previous cancer diagnoses or were diagnosed within 30 days of the genital warts were excluded.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
29 Nov 2017
Rapid onset opioids may allow for more effective treatment of breakthrough cancer pain as their pharmacokinetic profile closely mimics the pain’s time course
Christina Lau, 22 Oct 2015
A 21-gene expression assay can identify patients with early-stage breast cancer who can skip adjuvant chemotherapy without facing an increased risk of recurrence at 5 years.
Cathy Chow, PhD, 27 Aug 2015

HER2-positive breast cancer tends to be more aggressive, has worse patient prognosis, and responds less to treatment. A two-pronged approach to block the HER pathway via pertuzumab (Perjeta®, Roche), a first-in-class HER dimerization inhibitor, in combination with trastuzumab and chemotherapy, may offer more treatment options for HER2-positive metastatic breast cancer patients as well as those with early breast cancer. 

Saras Ramiya, 25 Oct 2017
The first patient-reported outcomes study on durvalumab treatment after chemoradiation in locally advanced non-small cell lung cancer (NSCLC) shows patients’ quality of life is similar to that of the patients who received placebo.